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ABSTRACT
Mutations in the Shwachman–Bodian–Diamond Syn-
drome (SBDS) gene cause Shwachman–Diamond
Syndrome (SDS), a rare congenital disease charac-
terized by bone marrow failure with neutropenia, ex-
ocrine pancreatic dysfunction and skeletal abnor-
malities. The SBDS protein is important for ribo-
some maturation and therefore SDS belongs to the
ribosomopathies. It is unknown, however, if loss of
SBDS functionality affects the translation of specific
mRNAs and whether this could play a role in the
development of the clinical features of SDS. Here,
we report that translation of the C/EBPα and -β
mRNAs, that are indispensible regulators of granulo-
cytic differentiation, is altered by SBDS mutations or
knockdown. We show that SBDS function is specif-
ically required for efficient translation re-initiation
into the protein isoforms C/EBP-p30 and C/EBP-
LIP, which is controlled by a single cis-regulatory up-
stream open reading frame (uORF) in the 5′ untrans-
lated regions (5′ UTRs) of both mRNAs. Furthermore,
we show that as a consequence of the C/EBP and
- deregulation the expression of MYC is decreased
with associated reduction in proliferation, suggest-
ing that failure of progenitor proliferation contributes
to the haematological phenotype of SDS. Therefore,
our study provides the first indication that distur-
bance of specific translation by loss of SBDS func-
tion may contribute to the development of the SDS
phenotype.
INTRODUCTION
The autosomal recessive disorder Shwachman–Diamond
syndrome (SDS) is caused by the expression of hypomor-
phic alleles carrying mutations in the Shwachman–Bodian–
Diamond syndrome (SBDS) gene (1). SDS is characterized
by bone marrow failure with neutropenia, exocrine pancre-
atic insufficiency and skeletal abnormalities (2). In mice,
complete loss of SBDS function is embryonic lethal (3),
indicating that SBDS is an essential gene. Over the past
decade, diverse functions for SBDS have been described,
including mitotic spindle stabilization (4), chemotaxis (5),
Fas ligand-induced apoptosis (6), cellular stress response (7)
and Rac2-mediated monocyte migration (8). Nonetheless,
there is now compelling evidence that SBDS functions in cy-
toplasmic ribosome maturation (9–13). Thus, SDS should
be considered a ribosomopathy caused by defective matura-
tion of the large ribosomal subunit. Studies with eukaryotic
SBDS and its yeast ortholog Sdo1 showed that SBDS coop-
erates with the GTPase elongation factor-like 1 (EFL1) to
catalyse removal of the eukaryotic initiation factor 6 (eIF6)
from the 60S ribosome subunit. eIF6 is critical for biogen-
esis and nuclear export of pre-60S subunits and prevents
ribosomal subunit association. Therefore, its release is re-
quired for ribosomal subunit association during translation
initiation (9,10,13–15). Currently, it is not known whether
SBDS deficiency mainly causes a general effect on mRNA
translation, or whether it results in aberrant translation of
specific mRNAs that contributes to the SDS phenotype.
Neutropenia is the most prominent haematopoietic ab-
normality seen in almost all SDS patients (16). Myeloid
progenitors derived from the bone marrow of SDS patients
have a reduced proliferation capacity with low frequency of
CD34+ cells and reduced colony forming ability (17).
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The CCAAT enhancer binding proteins C/EBP and
C/EBP are critical transcription factors for myelomono-
cytic lineage commitment, granulocyte differentiation and
macrophage function (18–20). Expression of C/EBP and
- proteins are strictly controlled at the mRNA-translation
initiation level (21–23). From consecutive initiation codons
in the C/EBPα mRNA three different protein isoforms
are synthesised. Extended-C/EBP or full-length C/EBP-
p42 is expressed from a cap-proximal GUG- (CUG for ro-
dents) or AUG-codon, respectively. A shorter N-terminally
truncated C/EBP-p30 isoform is translated from a dis-
tal AUG-codon. Translation from the distal AUG into
C/EBP-p30 requires re-association of ribosomes follow-
ing translation of a cis-regulatory upstream open reading
frame (uORF) in the 5′ untranslated region (5′ UTRs) of
the C/EBPα mRNA (Figure 1A) (22). Extended-C/EBP
is not further considered here since its expression from the
non-canonical GUG codon is usually very low.
C/EBP-p42 expression and induction of target genes
such as the CSF3R (colony stimulating factor 3 receptor
(granulocyte)) is essential for granulocytic differentiation
(24). In addition, C/EBP-p42 inhibits MYC expression,
which causes proliferating myeloid precursor cells to un-
dergo cell cycle arrest and entry into terminal differentiation
(25). C/EBP-p30 lacks the major part of the N-terminal
transactivation sequences but retains the C-terminal DNA-
binding domain and therefore competes with C/EBP-p42
or other C/EBPs for DNA binding (20). Moreover, solitary
expression of C/EBP-p30 blocks granulocytic differentia-
tion and results in an Acute Myeloid Leukaemia (AML)
like disease in mice (26,27). Translation of the C/EBPβ
mRNA into different protein isoforms is regulated in a sim-
ilar way (22,28). C/EBP-LAP* and -LAP proteins (LAP:
liver activating protein) are translated from cap-proximal
AUG-codons, while the truncated C/EBP-LIP (LIP: liver
inhibitory protein) protein is translated from a distal AUG-
codon through an uORF-dependent mechanism. LAP* ex-
pression is often very low since the LAP*-AUG codon lacks
a Kozak-consensus sequence that is required for efficient
translation initiation (29).
Translation of theC/EBPα and -β mRNAs is highly sen-
sitive to alterations in the translation machinery. Since both
factors play such a crucial role in the development of the
myelomonocytic lineage, we examined whether C/EBPα
and -β translation is regulated by SBDS and whether
C/EBP and - isoform expression is altered by SBDSmu-
tations. Here, we show that SBDS is required for efficient
translation of the truncated p30/LIP isoforms and that lym-
phoblastoid cell lines derived from SDS patients have re-
duced C/EBP-LIP levels. In addition, our study suggests
that SBDS deficiency indirectly suppresses the expression
ofMYC by increasing the C/EBP-p42/p30 isoform ratio.
Furthermore, our study suggests that this regulatory con-
nection between SBDS,C/EBP/ andMYC is decisive for
myeloid cell proliferation and differentiation. Our finding
is the first evidence of specific defective mRNA translation
in SDS, highlights the importance of the uORF-mediated
translation re-initiation mechanism that directs C/EBP
and - isoform expression for hematopoietic proliferation
and differentiation control.
MATERIALS AND METHODS
Cell culture
C33A cells were maintained in DMEM (Gibco) sup-
plemented with 10% fetal calf serum (FCS) and 1%
Penicillin/Streptomycin. HL-60 and HL-60 pCMV
C/EBP-p30flag overexpressing cells were commonly
maintained in RPMI (Gibco) supplemented with 10%
FCS and 1% Penicillin/Streptomycin. SDS patient-derived
lymphoblast cell lines including healthy wild type cell
were maintained in RPMI (Gibco) with 15% FCS and
1% Penicillin/Streptomycin at 37◦C with 5% CO2. For
neutrophil differentiation, 5.0 × 105 cells/ml were treated
with 5 M ATRA (Sigma) for 7–10 days. After treatment
of all-trans retinoic acid (ATRA), cells were harvested
and stained with Giemsa solution for morphologic dif-
ferentiation determination. The HL-60 cells expressing
C/EBP-p30flag were generated by retroviral transduc-
tion with a pMSCV-neo based construct and subsequent
selection of the transduced cells with G418 (1.8 mg/ml).
For knockdown of SBDS in HL-60 and C33A cells,
the cells were transduced with the lentiviral pLKO.1
shRNA vector against human SBDS (Sigma Aldrich)
or pLKO.1-scrambled shRNA as control followed by
selection of the transduced cells with puromycin (1.5
g/ml). For ectopic SBDS expression HL-60 or C33A cells
were transduced with a lentiviral pLVX-IRES-Neo based
construct and selected with G418 (1.8 mg/ml for HL60 and
0.8 mg/ml for C33A). Cell number and viability was
determined using the CASY electric field multi-channel cell
counting system following the manufacturers instruction.
Plasmid cloning and transfection
pLKO.1 shRNA vector against human SBDS was pur-
chased from Sigma Aldrich. shSBDS sequence: 5′-CCG
AGA AAT TGA TGA GCT AAT ctc gag ATT AGC TCA
TCA ATT TCT CGG-3′. For construction of the SBDS
overexpression vector, total mRNA was isolated from hu-
man lymphoblast cells using the RNeasy kit (Qiagen) and
SBDS cDNA was synthesized using the Transcriptor First-
strand cDNA Synthesis kit (Roche), which was used as a
PCR template. Forward primer: 5′-GTG AAT TCA TGT
CGA TCT TCA CCC CCA C-3′, Reverse primer: 5′-TTT
CTA GAA TCA TTC AAA TTT CTC ATC TCC TTC T-
3′. The PCR product was cloned into the pLVX-IRES-Neo
plasmid (Clontech) for lentiviral transduction and into the
pCDNA3 vector (Invitrogen) for transient transfection us-
ing the EcoRI and XbaI restriction sites. Wild-type rat
C/ebpα and -β cDNAs and uORF start codon mutant con-
structs (ratC/ebpα: ATG>ATC, ratC/ebpβ : ATG>ATT)
were previously cloned(22). C33A stable SBDS knockdown
or SBDS overexpression cells were transiently transfected
with wild-type or mutant rat C/EBP and - expression
plasmids using FugeneHD (Roche) following the manufac-
turer’s instructions.
Lentiviral and retroviral transduction
A total of 3.5–3.8 × 106 Hek293T cells were used for
co-transfection with pLKO.1 shSBDS vector (from Sigma
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Figure 1. Deregulated C/EBP protein isoform expression in SDS. (A) The human C/EBPα and -β mRNAs are presented with consecutive translation
initiation sites (arrowheads) and each of the protein isoforms and its size (*size of murine orthologs). Extended, p42, LAP* or LAP proteins are expressed
through regular translation initiation, omitting the uORF. Truncated p30 or LIP proteins are expressed through translation re-initiation by post-translation
ribosomes that first have translated the uORF. For detailed description of the uORFs and surrounding sequences, see (21–23). Expression of the Extended-
C/EBP isoform is generally weak because it uses the alternative GUG (CUG for murine) codon. Similarly, expression of the C/EBP-LAP* from a
non-Kozak AUG codon is mostly weak. (B) SBDS protein levels were detected in SDS patient-derived (SW18, SW74) and healthy control-derived (wt)
lymphoblastoid cells by immunoblotting. Long exposure shows the very low expression of wt SBDS in SW74 cells harbouring the homozygous 258 +
2T > C mutation. (C) The upper panels show immunoblots of C/EBP isoforms, SBDS and -tubulin as loading control in both SDS patient-derived
cells (SW18, SW74) and healthy control-derived cells (wt). The lower panels show immunoblots of 4E-BP1, phosphorylated-4EBP1 (P-4E-BP1), S6K1,
phosphorylated-S6K1 (P-S6K1) and -actin as loading control to monitor alterations in mTORC1 signalling (D) qRT-PCR analysis for endogenous
C/EBPβ mRNA levels in patient-derived cells (SW18, SW74) and healthy control cells (wt). (E) Immunoblots for MYC, SBDS and -tubulin (loading
control) in SDS patient-derived and healthy control-derived cells. (F) qRT-PCR analysis of MYC transcript levels in SDS patient-derived and healthy
control-derived cells. (G) Cell multiplication assay with patient-derived cells (SW18, SW74) and healthy control-derived cells (wt). Seven days after seeding
5 × 105 cells, cells were harvested and counted. Statistical differences were determined by Student’s t-tests. Error bars represent ±SD (n = 3), *P < 0.05,
**P < 0.01.
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Aldrich) or pLVX SBDS expression vector (10 g) together
with plasmid for viral packaging factors including pMDL-
RRE (6.5g), pCMV-VSVg (3.5 g) and pRSV-Rev (2.5
g) were transfected using the calcium phosphate method.
For retroviral transduction Phoenix A packaging cells were
transfected with the C/EBP-p30flag pMSCV-neo vector
with the calcium phosphate method. After 48 h, lenti-
or retrovirus-containing medium was harvested from the
transfected cells. Supernatant was collected by centrifuga-
tion and filtered using a 0.45m size PVDF filter. A total of
5.0 × 105 cells were incubated with virus-containing super-
natant with 4 g/ml (HL-60) or 8 g/ml (C33A) polybrene
for 24 h. To establish stable cell lines, puromycin or G418
was added to cells in fresh medium.
Immunoblotting
Cells were washed with cold phosphate buffered saline
(PBS) and harvested by scraping or centrifugation. Cells
were incubated with lysis buffer (50 mM Tris pH 7.5, 150
mM NaCl, 1mM EDTA pH 8.0, 1% TritonX-100 with
Protease- and Phosphatase Inhibitors (Roche)) for 30 min
at 4◦C or sonicated with a Bioruptor for 5 min at 4◦C. Af-
ter centrifugation with 13 000 rpm for 30 min at 4◦C, the
supernatant was obtained and used for immunoblot analy-
sis. The protein concentration measurement was done with
the Bradford assay (BioRad). Equal amount of protein ex-
tracts were loaded to 10 or 12% SDS-PAGE and trans-
ferred to a PVDF membrane (Biorad) by semi-dry blotting
for 1 h. Membranes were washed with washing buffer (Tris
buffered saline with 0.1% tween 20) and blocked for 1 h at
room temperature with blocking buffer (5% skimmilk solu-
tion). The primary antibodies, SBDS (S-15), C/EBP C18
(sc-9314) for human C/EBP and C/EBP 14AA (SC-61)
for rat C/EBP, C/EBP C19 (SC-150) for both human
and rat C/EBP, MYC (sc-40), -Tubulin (sc-8035), 4E-
BP1 (C-19) (all Santa Cruz Biotechnology) and Phosphory-
lated 4E-BP1 (Thr37/46) (9459), Phosphorylated p70-S6K
(Thr389) (9234), p70-S6K (9202) (Cell Signaling) and -
actin (691001) (MP Biomedicals) were diluted in blocking
buffer (1:400–1:10000). Incubation with primary antibody
was carried out at 4◦C overnight using an orbital shaker.
After washing with washing buffer for 10 min x 3 times, sec-
ondary antibody (1:5000) was added for 1 h at RT. Protein
signals were visualised using X-ray films (Amersham) with
chemiluminescence detection (Perkin Elmer).
C/EBP and- isoform ratio measurement
Immunoblotting was performed to visualise C/EBP and
- isoform expression as described above. To analyse iso-
form ratio, band intensity in immunoblot images was mea-
sured and quantified by densitometric analysis using Al-
phaimager software (Cell Bioscience) following the manu-
facturer’s instruction.
Luciferase assay
pcDNA3-based p42-Renilla and p30-Firefly (C/EBP) re-
porters were generated based on the previously described
pGL3-FL-C and pGL3-Tr-C (30): the Firefly luciferase
gene was exchanged by the Renilla luciferase gene in the
pGL3-FL-C and both reporters were re-cloned from
pGL3 into pcDNA3. For the pcDNA3-based LAP-Renilla
and LIP-Firefly (C/EBP) reporters, C/EBP-5′ UTR un-
til LAP initiation codon was cloned together with Renilla
(from pGL3) in pcDNA3 and C/EBP-sequences span-
ning the 5′ UTR and sequences until the LIP initiation
codon with a +1 frame shift (7 nt upstream of the AUG)
was cloned together with Firefly in pcDNA3. The control
reporters were generated by cloning Renilla (from pGL3)
or Firefly (from pGL4) genes in pcDNA3. Details of the
cloning strategy will be provided upon request. For the Lu-
ciferase assays 2.5× 103/well of C33A cells were seeded into
96 well plates. After 24 h, cells were transfected with p42-,
p30-, LAP or LIP reporters using FugeneHD (Roche). For
restoration of SBDS function a pCDNA3-based SBDS con-
struct or empty vector as control was co-transfected. Re-
nilla or Firefly luciferase vectors were co-transfected for
normalization of the reporter expression. After additional
48 h, cells were harvested and the Stop and Glow kit
(Promega) was used to measure luciferase activity.
Quantitative real time PCR (qRT-PCR) of mRNA
To detect mRNA transcription, total RNA was isolated
using the RNAeasy kit (Qiagen). cDNA synthesis was
performed with oligo dT primers using the Transcriptor
First Strand cDNA synthesis kit (Roche). GAPDH house
keeping gene was used for normalization of gene expres-
sion. C/EBPα: Forward primer: 5′-GGT TTT GCT CGG
ATA CTT GCC-3′, Reverse primer 5′-CAC CTC ATT
GGT CCC CCA G-3′; C/EBPβ: Forward primer: 5′-TTT
CGA AGT TGG ATG CAA TCG-3′, Reverse primer: 5′-
CAA CAA GCC CGT AGG AAC AT-3′; MYC: Forward
primer: 5′-TCA AGA GGT GCC ACG TCT CC-3′, Re-
verse primer: 5′-TCT TGG CAG CAG GAT AGT CCT-
3′; GAPDH: Forward primer: 5′- GTC AGT GGT GGA
CCTGACCT-3′, Reverse primer: 5’-ACCTGGTGCTCA
GTG TAG CC-3’; SBDS: Forward primer: 5′-ACG TGC
TCA CAT GAG GCT T CG-3′, Reverse primer: 5′-CAG
CCC GGG TCA ATC AGA CAT-3′.
RESULTS
C/EBP-LIP expression is diminished in SDS-derived lym-
phoblast cells
To investigate whether SBDSmutationsmay affectC/EBP-
mRNA translation, we examined C/EBP isoform expres-
sion in two SDS patient-derived lymphoblast cell lines com-
pared to lymphoblasts derived from a healthy individual by
immunoblotting. The SW74 cell line carries the homozy-
gous SBDS mutation 258 + 2T > C, a common muta-
tion in SDS resulting in very low expression of wild type
SBDS compared to the healthy control (wt) (Figure 1B);
the SW18 cell line carries the heterozygous SBDS muta-
tions 258 + 2T > C and 505C > T resulting in reduced
levels of mutant SBDS (Figure 1B) (13). The C/EBP iso-
forms LAP and LIP were both expressed in the control cells
(wt). By contrast, LIP expression was hardly detectable in
the patient-derived cells (SW18 and SW74) while LAP lev-
els were similar to the control (Figure 1C). We have shown
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before that expression of LIP is activated by mTORC1 sig-
nalling and that inhibition of mTORC1 results in suppres-
sion of LIP both in cell culture and in vivo (22,28,31). To ex-
amine whether SBDS deficiency reduces mTORC1 activity
and thereby regulates LIP expression, we analysed the ex-
pression and the phosphorylation status of two mTORC1
targets, the 4E-binding protein 1 (4E-BP1) and the p70 ri-
bosomal protein S6 kinase 1 (S6K1p70). SBDS deficiency
does not significantly diminish the phosphorylation sta-
tus of 4E-BP1 or S6K1 (Figure 1C, lower panels). Thus,
mTORC1 signalling and its major downstream translation
control pathways through 4E-BP1 or S6K1p70 seem not to
be involved in the SBDS-dependent regulation of LIP ex-
pression. Quantitative Real Time PCR (qRT-PCR) analysis
showed that C/EBPβ mRNA expression was higher in the
patient derived SW18 and SW74 cells (Figure 1D), although
this did not result in higher protein expression. Others have
shown that the ratio of C/EBP-LAP over C/EBP-LIP
controls expression ofMyc (32). BothMYC transcript and
protein levels were reduced in both SBDS mutant cell lines
SW18 and SW74 compared to the control cells (wt) (Fig-
ure 1E and F), which was associated with a reduced prolif-
eration capacity of the SW18 and SW74 cells (Figure 1E).
Hence, two different pathological SBDS mutations corre-
late with reduced C/EBP-LIP and MYC expression and
reduced proliferation.
uORF-dependent regulation of C/EBP-p30 and C/EBP-
LIP expression by SBDS levels
Lymphoid cells do not express C/EBP. To further exam-
ine the relation between SBDS expression and C/EBP and
- expression, we performed SBDS knockdown in the hu-
man promyelocytic leukaemia cell line HL-60 that express
endogenous C/EBP and C/EBP. SBDS knockdown by
lentiviral SBDS-shRNA resulted in reduced expression of
C/EBP-p30 andC/EBP-LIP (Figure 2AandB) and con-
comitant lower p30/p42 and LIP/LAP ratios. Similar as de-
scribed for the patient-derived lymphoblasts SBDS knock-
down did not reduce phosphorylation of 4E-BP1 or S6K1,
suggesting that mTORC1 signalling is not involved in the
downregulation of p30/LIP upon SBDS knockdown (Fig-
ure 2A, lower panels). No significant change was observed
in C/EBPα and C/EBPβ mRNA levels. Overexpression of
SBDS in HL-60 cells led to an increased expression of p30
and LIP resulting in higher LIP/LAP ratios without chang-
ing C/EBPα or -β mRNA levels (Supplementary Figure
S1A and B). These data indicate that SBDS and expression
of p30 or LIP might be functionally correlated.
To examine the relevance of uORF-controlled transla-
tion of the C/EBPα and -β mRNAs by SBDS levels we
transiently expressed wild-type cDNA constructs of rat
C/EBPα and -β as well as constructs thereof carrying mu-
tations that interfere with uORF-function in C33A hu-
man cervix carcinoma cells that expressed either SBDS-
shRNA for knockdown or SBDS-cDNA for overexpres-
sion. We used the C33A cell line for these studies because
these cells tolerate high expression of p42 without inducing
the usual p42-associated cell cycle arrest that would compli-
cate analysis (33). Similar to what we observed for endoge-
nous C/EBPs, knockdown of SBDS resulted in a reduction
of p30/p42 and LIP/LAP ratios through downregulation
of p30 or LIP, respectively (Figure 2C and D), while SBDS
overexpression upregulates p30 and LIP expression (Sup-
plementary Figure S1C and D). Also in this case, SBDS
knockdown did not alter mTORC1 signalling (Figure 2C,
lower panels).
We have shown before that the conserved uORF in the
vertebrate C/EBPα and -β mRNAs is required for transla-
tion re-initiation from the p30 or LIP translation-initiation
codon, respectively (21,22). Mutation of the uORF-AUG
into a non-AUGcodon (ATC forC/ebpα; ATT forC/ebpβ)
that eliminates uORF-function resulted in complete loss of
p30 or LIP expression independent of SBDS knockdown
or overexpression but did not affect p42 or LAP expres-
sion (Figure 2E and F). These data indicate that regulation
of p30/LIP by SBDS levels depends on the cis-regulatory
function of the uORFs in theC/EBPmRNAs as was shown
before for other translational control pathways (22,28).
Loss of SBDS function specifically affects translation re-
initiation
To examine the effect of SBDS function on translation
initiation versus uORF-mediated re-initiation we used a
reporter system based on the rat C/EBPα-mRNA or
C/EBPβ-mRNA structures (30,34,35). Briefly, from the
p42- or LAP-reporter, expression of Renilla luciferase
can only be achieved by translation initiation and omis-
sion of uORF-translation, reminiscent to C/EBP-p42 or
C/EBP-LAP translation (Figure 3A). From the p30- or
LIP-reporter, expression of Firefly luciferase can only be
achieved through a translation re-initiation mechanism by
ribosomes that have first translated the uORF, resumed
scanning and initiated at the downstream AUG codons,
which is reminiscent of C/EBP-p30 or C/EBP-LIP
translation. In the latter case, eventual translation from the
C/EBP-p42 or C/EBP-LAP AUG-codons do not run
into the Firefly luciferase coding frames and therefore are
not detected since a reading frame shift is introduced just
upstream of the p30/LIP initiation sites (Figure 3A) (22).
To normalize against effects not related to initiation/re-
initiation efficiency, Renilla and Firefly luciferase expres-
sion control vectors were co-transfected along with the Re-
nilla and Firefly reporters, respectively.
C33A cell lines expressing either SBDS-shRNA or
SBDS-cDNAwere transiently transfected with the reporter
and control constructs and used for the luciferase assay.
In the SBDS knockdown cells, translation initiation into
p42-Renilla was not altered while translation re-initiation
into p30-Firefly is strongly reduced, resulting in signifi-
cant lower p30-Firefly/p42-Renilla ratio (Figure 3B, left
side). Similarly, in the SBDS knockdown cells initiation
into LAP-Renilla was slightly enhanced while re-initiation
was strongly reduced, resulting in significant lower LIP-
Firefly/LAP-Renilla ratio (Figure 3B, right side). More-
over, the negative effects of SBDS knockdown on p30-
Firefly and LIP-Firefly expression could be rescued by ad-
ditional overexpression of SBDS resulting in normalised
p30-Firefly/p42-Renilla and LIP-Firefly/LAP-Renilla ra-
tios comparable to the control (Figure 3C). Contrary to the
SBDS knockdown, overexpression of SBDS did not greatly
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Figure 2. SBDS is required for efficient C/EBP-p30 and C/EBP-LIP expression. Expression of the endogenous (A) human C/EBP (p42 and p30)
or (B) human C/EBP proteins (43 kDa LAP and 20 kDa LIP) in HL-60 cells with stable SBDS knockdown (shSBDS) or control (scrambled shRNA)
by immunoblotting, and quantification of p30/p42 or LIP/LAP ratio and qRT-PCR analysis of transcript levels at the right. The lower panels in (A)
show immunoblots of 4E-BP1, phosphorylated-4E-BP1 (P-4E-BP1), S6K1, phosphorylated-S6K1 (P-S6K1) and -actin as loading control to monitor
alterations in mTORC1 signalling. Immunoblots of (C) rat C/EBP (p42 and p30) or (D) rat C/EBP (38 kDA LAP*, 34 kDa LAP and 20 kDa LIP)
expression in C33A cells with stable SBDS knockdown (shSBDS) and control (scrambled shRNA) transiently transfected with wild-type rat C/ebpα or
wild-type ratC/ebpβ expression plasmids, respectively. Quantification of isoform ratio is shown at the top. The lower panels show immunoblots of 4E-BP1,
phosphorylated-4E-BP1 (P-4E-BP1), S6K1, phosphorylated-S6K1 (P-S6K1) and -actin as loading control to monitor alterations in mTORC1 signalling.
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C/ebpα or -β cDNA expression vectors. Statistical differences in the mRNA levels and isoform ratios were determined by Student’s t-tests. Error bars
represent ±SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.005.
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Figure 3. Loss of SBDS function specifically affects translation re-initiation. (A) Representation of the p42- or LAP-Renilla luciferase and p30- or LIP-
Firefly luciferase reporters. Renilla luciferase expression from the p42/LAP-reporters results from translation-initiation omitting the uORF, while Firefly
luciferase expression from the p30/LIP-reporters is achieved through uORF-mediated translation re-initiation (30). (B) C33A cells with stable SBDS
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< 0. 005.
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affect the levels of the individual reporters, resulting in simi-
lar p30-Firefly/p42-Renilla or LIP-Firefly/LAP-Renilla ra-
tios (Figure 3D).
Therefore, collectively our experiments with C/EBP
and - cDNAs and the related reporter systems suggest that
SBDS levels affect uORF-mediated translation re-initiation
but have no significant effect on regular translation initia-
tion.
SBDS knockdown reduces MYC expression through
C/EBP p30/p42 ratio
MYC is required for the proper balance between
haematopoietic stem cell self-renewal and differentia-
tion (36). Conditional elimination of Myc in the bone
marrow (BM) of mice results in severe cytopenia and
accumulation of HSCs (37). Deregulated activation of
MYC has been found in many types of human lymphoma
and leukaemia (38). MYC mRNA expression is regulated
by p42 through the inhibitory interaction with E2F at
the MYC promoter while p30 fails to do so (25,39,40).
For example, treatment of HL-60 cells with the growth
arrest and apoptosis inducing drug CDDO (2-Cyano-3,12-
dioxooleana-1,9-dien-28-oic acid) causes a translational
upregulation of C/EBPα accompanied by a translational
downregulation of p30 and an increase in the p42/p30
ratio, which results in strong reduction of MYC mRNA
levels associated with inhibition of proliferation and induc-
tion of neutrophil differentiation (41). In HL-60 cells with
stable SBDS knockdown and concomitant reduction of the
C/EBP p30/p42 and C/EBP LIP/LAP ratios (Figure
2A and B) the expression ofMYC protein and mRNA was
decreased (Figure 4A and B). To examine whether down-
regulation of p30 is required for MYC suppression, we
overexpressed a flag-tagged C/EBP-p30 (p30flag) protein
in HL-60 cells. Overexpression of p30flag rescued MYC
protein and mRNA expression in HL-60 cells with stable
SBDS knockdown (Figure 4C and B), showing that MYC
expression depends on p30. Similarly, cell multiplication
was reduced upon SBDS knockdown in HL-60 cells, which
could be restored by p30flag overexpression (Figure 4D).
To corroborate our data and literature (39) suggesting
that p42 inhibits MYC expression, we examined MYC
expression in a K562 chronic myeloid leukaemia (CML)
cell line stably expressing a C/EBP-p42-estrogen receptor
(p42ER) fusion protein (39). Proteins fused to an oestro-
gen receptor domain (ER) are sequestered in the cytoplasm
through binding to heat shock proteins (HSPs). Addition of
the oestrogen receptor ligand -estradiol to the cell culture
medium results in relocation of p42ER to the nucleus and
activation of C/EBP-p42-transcriptional functions. Acti-
vation of p42ER by -estradiol addition resulted in strong
repression of MYC mRNA and protein, which was asso-
ciated with reduced proliferation capacity (Supplementary
Figure S2A–C). In the control experiment, activation of the
unfused ER domain had no effect on MYC expression or
cell proliferation (Supplementary Figure S2D–F).
To substantiate the association between expression of
p30 and MYC, we reduced p30 expression by inhibition of
mTOR signalling (22). Treatment of HL-60 cells with the
mTOR inhibitor PP242 resulted in a reduced p30/p42 ra-
tio, reduction of MYC mRNA and protein expression and
reduced proliferation capacity (Figure 4E-G). Overexpres-
sion of p30flag rescued both MYC mRNA and protein lev-
els despite the inhibition of mTOR by PP242 (Figure 4H
and I). The proliferation capacity was partially restored by
p30 overexpression (Figure 4J) suggesting that the C/EBP
isoform ratio is decisive for MYC expression in HL-60 cells
which however only partially contributes to mTORC1 me-
diated proliferation control. Collectively the data suggest
that MYC expression is regulated by SBDS through trans-
lational regulation of the p30/p42 C/EBP isoform ratio.
Deregulation of C/EBP p30 expression impedes neutrophil
differentiation
HL-60 cells differentiate into the neutrophil lineage in re-
sponse to ATRA treatment. During differentiation, the ex-
pression of p30, but not of p42 was reduced, resulting in a
strong reduction in the p30/p42 ratio (Figure 5A). Tran-
script levels of C/EBPα were reduced at the final day 6
(Figure 5B). MYC mRNA and protein levels rapidly and
strongly declined during differentiation (Figure 5A and B).
Intriguingly, SBDS mRNA and protein levels were also re-
duced during differentiation (Figure 5A and B), as reported
for other cell lines (42–44). Overexpression of p30flag re-
sulted in delayed suppression of MYC mRNA (Figure 5A)
and protein (Figure 5C). In addition, endogenous p30 and
SBDS expression are delayed (Figure 5B and C). Further-
more, overexpression of p30flag is sufficient to sustain pro-
liferation of HL-60 cells during ATRA treatment (Figure
5D). Compared with control HL-60 cells, at day seven of
ATRA treatment p30flag overexpression induced a signif-
icant reduction in the number of terminally differentiated,
proliferation-arrested cells, with expansion of proliferative
myelocytes to more than 20% (Figure 5E). Finally, SBDS
knockdown did not alter ATRA-induced differentiation of
HL-60 cells (Figure 5F).
DISCUSSION
Recent studies have defined the role of SBDS in ribosome
maturation (9,10,13). However, so far a clear connection be-
tween reduced ribosomal SBDS function in SDS patients,
deregulated translation and the disease phenotype is lack-
ing. Our data for the first time demonstrate that translation
of specific mRNAs, namely the C/EBPα and -β mRNAs,
is affected by loss of SBDS function. Different isoforms,
full-length (p42 and LAP) and truncated (p30 and LIP), are
translated from both C/EBPα and -β mRNAs through the
use of different translation initiation sites. Interestingly, re-
duced SBDS function by either shRNA mediated knock-
down or by mutations in SDS patient-derived B-lymphoid
cells affected in particular translation re-initiation into the
truncated p30 and LIP isoforms leaving translation into
the full-length isoforms by regular initiation largely unaf-
fected. The same reduction in re-initiation but not initi-
ation by SBDS knockdown was observed with luciferase
reporters mimicking C/EBPα-mRNA (p42/p30 reporters)
or C/EBPβ-mRNA (LAP/LIP reporters) regulation, ren-
dering it independent of effects on protein turnover. More-
over, re-initiation from the reporters was restored in SBDS
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Figure 4. SBDS-dependent C/EBP p30/p42 isoform ratio regulates MYC expression and cell proliferation in HL-60 cells. (A) Immunoblots showing
endogenous MYC, C/EBP, SBDS and -Tubulin (loading control) protein expression in HL-60 cells with stable knockdown of SBDS (shSBDS) or
control (scrambled shRNA). Quantification of the p30/p42 isoform ratio and MYC protein levels are shown on the right panel. (B) qRT-PCR analysis
of endogenous MYC mRNA expression level in HL-60 cells and HL-60-p30flag overexpressing cells with stable knockdown of SBDS (shSBDS) or con-
trol (scrambled shRNA). (C) HL-60 cells stably overexpressing C/EBP-p30flag and knockdown of SBDS (shSBDS) or control (scrambled shRNA).
Immunoblot shows endogenous MYC, C/EBP, SBDS and -tubulin (loading control) protein expression. Quantification of the p30/p42 isoform ratio
and MYC protein levels are shown on the right panel. (D) Cell multiplication assay with HL-60 cells expressing scrambled shRNA (control), shSBDS
(SBDS knockdown), shSBDS/C/EBP-p30flag or scrambled shRNA/C/EBP-p30flag. Seven days after seeding 5 × 105 cells, cells were harvested and
counted. Different letters (a, b, c, d) indicate significant differences in cell numbers determined by one-way-ANOVA. Error bars represent ±SD (n = 3), P
< 0.05. (E) HL-60 cells were treated with 1 M PP242 or DMSO as a control for 48 h. Immunoblots show expression of MYC, p42, p30flag, p30, p4E-
BP1, 4E-BP1, SBDS and -Tubulin (loading control). The phosphorylation levels of 4E-BP1 indicate mTORC1 activity. Quantification of the p30/p42
isoform ratio and MYC protein levels are shown on the right panel. (F) EndogenousMYCmRNA levels by qRT-PCR. (G) Cell multiplication assay with
HL-60 cells incubated with 1 M PP242 or DMSO (solvent). Seven days after seeding 5 × 105 cells, cells were harvested and counted. (H) HL-60-p30flag
overexpressing cells were treated with 1 MPP242 or DMSO for 48 h and expression of MYC, p42, p30flag, p30, p4E-BP1, 4E-BP1, SBDS and -Tubulin
(loading control) was examined by immunoblotting. Quantification of the p30/p42 isoform ratio and MYC protein levels are shown on the upper panel.
(I) EndogenousMYC mRNA transcription levels and (J) the proliferation capacity were measured as described above. For all panels except for panel D,
statistical differences were determined by Student’s t-tests. Error bars represent ±SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.005.
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Figure 5. SBDS dependent C/EBP-p30 expression regulates MYC expression and cell proliferation during neutrophil differentiation. (A) HL-60 cells
undergo neutrophil differentiation with 5 MATRA treatment. Immunoblots show expression of MYC, p42, p30, SBDS and -tubulin (loading control)
at days 0, 2, 4 and 6 of treatment (D = days). (B) qRT-PCR analysis of mRNA levels ofMYC, C/EBPα, and SBDS during neutrophil differentiation. (C)
Immunoblots show expression of MYC, p42, p30, SBDS or -tubulin (loading control) in HL-60 control cells (left) or HL-60 cells stably overexpressing
C/EBP-p30flag (right). (D) Cell multiplication assay with HL-60 or HL-60 cells expressing C/EBP-p30flag treated with 5 MATRA at day 0. At day 0,
5× 105 cells were seeded and cell numbers were determined at the indicated time points (D= day). (E) HL-60 or HL-60 expressing C/EBP-p30flag treated
with 5 MATRA for 7 days (D7). (F) HL-60 cells expressing shSBDS for stable knockdown of SBDS or expressing control scrambled shRNA treated with
5 MATRA for 7 days (D7). For (E) and (F) Giemsa staining was used for morphological analysis (magnification x200). At the right, the distribution of
neutrophil phenotypes is shown. All asterisks indicate significant differences between control cells and p30flag overexpressing cells or control and shSBDS
expressing cells determined by Student’s t-tests. Error bars represent ±SD (n = 3), *P < 0.05, **P < 0.01, ***P < 0.005.
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knockdown cells by ectopic overexpression of SBDS. This
suggests that reduced SBDS function does not in general af-
fect all translation events but may specifically affect trans-
lation re-initiation. Prerequisite for translation re-initiation
at the p30 and LIP initiation codons is an initial transla-
tion of a cis-regulatory small uORF in the C/EBPα and -
β mRNAs. This generates post-termination ribosomal sub-
units that are able to scan the mRNA further to the down-
stream initiation codon and re-initiate translation.
So far we do not know which step of the C/EBPα/β
mRNA-specific translational event is inhibited by the re-
duced SBDS function. It may involve reduced recognition
of the uORF initiation codon, efficiency of re-initiation
at the downstream initiation codon or scanning along
the mRNA following uORF translation. It seems that re-
initiation after uORF translation is regulated by different or
additionalmechanisms compared to general cap-dependent
translation initiation andwe are only at the beginning of un-
derstanding the underlying mechanisms. For example, for
Drosophila it was shown that the DENR-MCT-1 complex
specifically affects re-initiation events after uORF transla-
tion of a specific set of mRNAs in proliferating cells (45),
and in Arabidopsis eIF3H is required for mTOR-mediated
translation re-initiation (46). Future experiments have to
address the molecular basis of the effect of SBDS deple-
tion on C/EBPα and -β mRNA translation. In addition it
will be interesting to see whether the translation of other
mRNAs harbouring uORFs that promote re-initiation are
sensitive to reduced SBDS function. Genome-wide ribo-
some profiling could reveal transcripts and specific trans-
lation modes that are affected by loss of SBDS function.
SBDS promotes a conformational switch in the GTPase
EFL1 that displaces eIF6 from the 60S subunit by compet-
ing for an overlapping binding site (12). Displacement of
eIF6 allows joining of the 60S and 40S subunits to gener-
ate actively translating 80S ribosomes. In addition, it was
postulated based on in vitro reconstitution experiments that
eIF6 may act in the dissociation of post-termination ribo-
somes and thereby stimulates ribosomal subunit recycling
(47). It has been shown recently that experimental reduc-
tion of eIF6 levels reduce expression levels of LIP (48). The
authors discuss the possibility that the anti-association ac-
tivity of eIF6 is required to circumvent formation of inac-
tive 80S after uORF translation termination and allowing
post-termination 40S to re-initiate at a downstream initi-
ation codon. If eIF6 is indeed required for keeping post-
termination 40S ribosomal subunits free for re-initiation at
downstream sites then SBDS would facilitate this by releas-
ing eIF6. However, other yet to be identified mechanisms
could be responsible for the regulation of p30 and LIP ex-
pression by SBDS.
Another important question addresses the biological
consequence of reduced C/EBP and - truncated iso-
form expression in the context of SBDS deficiency. Unfor-
tunately, the SDS patient derived B-cells and the wild-type
SBDS control cells do not express endogenous C/EBP.
Therefore, we examined the biological effects of reduced
SBDS function in the promyelocytic leukaemia cell lineHL-
60 in response to shRNA mediated SBDS knockdown be-
cause this cell line expresses both C/EBP and - endoge-
nously.KnockdownofSBDS delayed increase in viable cells
counts compared to control shRNA-expressing cells, indi-
cating that cell proliferation was attenuated in the SBDS
knockdown cells. Attenuation of cell proliferation corre-
lated with the decreased expression of the proto-oncogene
MYC both at the mRNA and protein level in response
to SBDS knockdown. The effect on MYC protein levels
seems to be much stronger than observed for mRNA lev-
els (Figure 4, A, C and E), suggesting that additional reg-
ulation at the post-transcriptional level may be involved. It
has been shown earlier thatMYC is a transcriptional target
of both C/EBP and - and that the full-length isoforms
act as repressors of MYC transcription (25,32). Further-
more, alteration of theC/EBP isoform ratio through treat-
ment of HL-60 cells with the drug CDDO that downregu-
lates p30 expression strongly reduces MYC mRNA levels
and inhibits proliferation (41), similar to what we observed
in response to the reduction of p30 expression through
mTOR inhibition. Therefore, we hypothesize that the al-
tered C/EBP ratio in response to SBDS knockdown leads
to the inhibition of MYC expression, which then results
in the attenuation of proliferation. This hypothesis is sup-
ported by the observation that constitutive expression of the
p30flag isoform restores both MYC expression and prolif-
eration in SBDS knockdown cells. Interestingly, decreased
MYCmRNA levels were also observed in embryonic brain,
liver, cartilage and bone tissue from an SDS mouse model
(compound heterozygotes for SBDS null and SBDS-R126T
alleles) and in the pancreas of a pancreas-specific version of
this SDS mouse model. Decreased MYC expression in the
pancreas was, however, shown to depend on the upregula-
tion of p53 upon loss of SBDS function (49). HL-60 cells
don’t express functional p53 indicating that impairment of
SBDS function might result in the downregulation of MYC
and inhibition of proliferation by a different mechanism,
which as we propose is the changed C/EBP isoform ratio.
Both p42 and LAP have been shown to inhibit cell prolifer-
ation through repression of E2F target genes, while p30 and
LIP counteract this function and thereby support prolifer-
ation (31,50). Therefore, apart from the downregulation of
MYC, the reduced expression of other E2F target genes in
response to the changedC/EBPα/β isoform ratio is proba-
bly involved in slowing down cell proliferation upon SBDS
deficiency.
A prominent feature of SDS patients is bonemarrow fail-
ure associated with neutropenia. Such a neutropenia could
be caused by a failure of progenitor cells to either differ-
entiate or to proliferate because the latter situation would
strongly reduce the number of cells that undergo differentia-
tion. Contradicting results have been published concerning
the cause of neutropenia. Studies using shRNA-mediated
downregulation of SBDS expression in murine hematopoi-
etic progenitors or using an sbds deficientmousemodel with
deletion of SBDS predominantly in themyeloid lineage sug-
gest that loss of SBDS interferes with terminal differentia-
tion of neutrophils (51,52). Although the exact mechanism
of this differentiation block is not known, it is accompanied
with reduced expression of the myeloid transcription factor
retinoid acid receptormRNA, upregulation of p53 and in-
duction of apoptosis (52). On the other hand, it was shown
that haematopoietic progenitors derived from SDS patients
have proliferation defects (42). Similarly, SBDS knockdown
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in the 32Dmyeloblast cell line resulted in reduced prolifera-
tion without affecting differentiation (44). The observation
that SBDS expression is high in undifferentiated 32D cells
but decreases upon differentiation (44) also speaks in favour
for a function in proliferating cells.
C/EBPα is a decisive factor for neutrophil differentiation
that at the same time is involved in proliferation control. Its
deletion in mice results in a block in granulocyte differen-
tiation and enhanced self-renewal capacity of haematopoi-
etic stem cells (53). The p42 isoform ofC/EBPα induces the
transcription of CSF3R, C/EBP andNE (neutrophil elas-
tase), which are decisive for differentiation (24,54). On the
other hand, mutations of C/EBPα have been detected in
AML patients, some of the mutations resulting in expres-
sion of only the truncated isoform and preventing expres-
sion of the p42 isoform (55). Knockin mice expressing only
p30 isoform develop leukaemia and it has been suggested
that p30 acts as a negative inhibitor of p42 by blocking the
expression of differentiation related genes and by stimulat-
ing proliferation (26).
Interestingly, during the differentiation of HL-60 cell, we
observed downregulation of SBDS expression similarly to
what has been shown in 32D cells (44) with high levels of
SBDS correlating with high levels of p30 and high levels
of MYC in the early phase where the cells still proliferate.
However, at later stages of the differentiation process when
cells stop proliferating, SBDS was downregulated concomi-
tantly with p30 and MYC. Thus, our results support the
idea that in SDS patients the reduced levels of SBDS protein
preferentially affect cell proliferation and thus expansion of
the early progenitor pool rather than the differentiation pro-
cess per se.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We would like to thank Daniel G. Tenen for C/EBP-
p42ER K526 Cells.
FUNDING
Leibniz Graduate School on Ageing and Age-Related Dis-
eases (LGSA) [through a grant to C.F.C, to K.I.]; a spe-
cialist Programme from Bloodwise [12048 to A.J.W.]; Medi-
cal Research Council [MC U105161083]; a Wellcome Trust
strategic award to the Cambridge Institute for Medical Re-
search [100140]; a core support grant from the Wellcome
Trust and MRC to the Wellcome Trust – Medical Research
Council Cambridge StemCell Institute, Ted’s Gang and the
Cambridge NIHR Biomedical Research Centre. Funding
for open access charge: Leibniz Institute on Aging - Fritz
Lipmann Institute.
Conflict of interest statement.None declared.
REFERENCES
1. Boocock,G.R., Morrison,J.A., Popovic,M., Richards,N., Ellis,L.,
Durie,P.R. and Rommens,J.M. (2003) Mutations in SBDS are
associated with Shwachman-Diamond syndrome. Nat. Genet., 33,
97–101.
2. Dror,Y., Donadieu,J., Koglmeier,J., Dodge,J., Toiviainen-Salo,S.,
Makitie,O., Kerr,E., Zeidler,C., Shimamura,A., Shah,N. et al. (2011)
Draft consensus guidelines for diagnosis and treatment of
Shwachman-Diamond syndrome. Ann. N.Y. Acad. Sci., 1242, 40–55.
3. Zhang,S., Shi,M., Hui,C.C. and Rommens,J.M. (2006) Loss of the
mouse ortholog of the shwachman-diamond syndrome gene (Sbds)
results in early embryonic lethality.Mol. Cell. Biol., 26, 6656–6663.
4. Austin,K.M., Gupta,M.L. Jr, Coats,S.A., Tulpule,A.,
Mostoslavsky,G., Balazs,A.B., Mulligan,R.C., Daley,G., Pellman,D.
and Shimamura,A. (2008) Mitotic spindle destabilization and
genomic instability in Shwachman-Diamond syndrome. J. Clin.
Invest., 118, 1511–1518.
5. Stepanovic,V., Wessels,D., Goldman,F.D., Geiger,J. and Soll,D.R.
(2004) The chemotaxis defect of Shwachman-Diamond syndrome
leukocytes. Cell Motil. Cytoskeleton, 57, 158–174.
6. Rujkijyanont,P., Watanabe,K., Ambekar,C., Wang,H., Schimmer,A.,
Beyene,J. and Dror,Y. (2008) SBDS-deficient cells undergo
accelerated apoptosis through the Fas-pathway. Haematologica, 93,
363–371.
7. Ball,H.L., Zhang,B., Riches,J.J., Gandhi,R., Li,J., Rommens,J.M.
and Myers,J.S. (2009) Shwachman-Bodian Diamond syndrome is a
multi-functional protein implicated in cellular stress responses. Hum.
Mol. Genet., 18, 3684–3695.
8. Leung,R., Cuddy,K., Wang,Y., Rommens,J. and Glogauer,M. (2011)
Sbds is required for Rac2-mediated monocyte migration and
signaling downstream of RANK during osteoclastogenesis. Blood,
117, 2044–2053.
9. Finch,A.J., Hilcenko,C., Basse,N., Drynan,L.F., Goyenechea,B.,
Menne,T.F., Gonzalez Fernandez,A., Simpson,P., D’Santos,C.S.,
Arends,M.J. et al. (2011) Uncoupling of GTP hydrolysis from eIF6
release on the ribosome causes Shwachman-Diamond syndrome.
Genes Dev., 25, 917–929.
10. Menne,T.F., Goyenechea,B., Sanchez-Puig,N., Wong,C.C.,
Tonkin,L.M., Ancliff,P.J., Brost,R.L., Costanzo,M., Boone,C. and
Warren,A.J. (2007) The Shwachman-Bodian-Diamond syndrome
protein mediates translational activation of ribosomes in yeast. Nat.
Genet., 39, 486–495.
11. Narla,A. and Ebert,B.L. (2010) Ribosomopathies: human disorders
of ribosome dysfunction. Blood, 115, 3196–3205.
12. Weis,F., Giudice,E., Churcher,M., Jin,L., Hilcenko,C., Wong,C.C.,
Traynor,D., Kay,R.R. and Warren,A.J. (2015) Mechanism of eIF6
release from the nascent 60S ribosomal subunit. Nat. Struct. Mol.
Biol., 22 , 914–919.
13. Wong,C.C., Traynor,D., Basse,N., Kay,R.R. and Warren,A.J. (2011)
Defective ribosome assembly in Shwachman-Diamond syndrome.
Blood, 118, 4305–4312.
14. Burwick,N., Coats,S.A., Nakamura,T. and Shimamura,A. (2012)
Impaired ribosomal subunit association in Shwachman-Diamond
syndrome. Blood, 120, 5143–5152.
15. Ceci,M., Gaviraghi,C., Gorrini,C., Sala,L.A., Offenhauser,N.,
Marchisio,P.C. and Biffo,S. (2003) Release of eIF6 (p27BBP) from
the 60S subunit allows 80S ribosome assembly. Nature, 426, 579–584.
16. Donadieu,J., Leblanc,T., Bader Meunier,B., Barkaoui,M.,
Fenneteau,O., Bertrand,Y., Maier-Redelsperger,M., Micheau,M.,
Stephan,J.L., Phillipe,N. et al. (2005) Analysis of risk factors for
myelodysplasias, leukemias and death from infection among patients
with congenital neutropenia. Experience of the French Severe
Chronic Neutropenia Study Group. Haematologica, 90, 45–53.
17. Dror,Y. and Freedman,M.H. (1999) Shwachman-Diamond
syndrome: an inherited preleukemic bone marrow failure disorder
with aberrant hematopoietic progenitors and faulty marrow
microenvironment. Blood, 94, 3048–3054.
18. Bereshchenko,O., Mancini,E., Moore,S., Bilbao,D., Mansson,R.,
Luc,S., Grover,A., Jacobsen,S.E., Bryder,D. and Nerlov,C. (2009)
Hematopoietic stem cell expansion precedes the generation of
committed myeloid leukemia-initiating cells in C/EBPalpha mutant
AML. Cancer Cell, 16, 390–400.
19. Bradley,M.N., Zhou,L. and Smale,S.T. (2003) C/EBPbeta regulation
in lipopolysaccharide-stimulated macrophages.Mol. Cell. Biol., 23,
4841–4858.
20. Cleaves,R., Wang,Q.F. and Friedman,A.D. (2004) C/EBPalphap30,
a myeloid leukemia oncoprotein, limits G-CSF receptor expression
but not terminal granulopoiesis via site-selective inhibition of
C/EBP DNA binding. Oncogene, 23, 716–725.
 at U
niversity of Cam
bridge on January 18, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2016 13
21. Calkhoven,C.F., Bouwman,P.R., Snippe,L. and Ab,G. (1994)
Translation start site multiplicity of the CCAAT/enhancer binding
protein alpha mRNA is dictated by a small 5′ open reading frame.
Nucleic Acids Res., 22, 5540–5547.
22. Calkhoven,C.F., Muller,C. and Leutz,A. (2000) Translational control
of C/EBPalpha and C/EBPbeta isoform expression. Genes Dev., 14,
1920–1932.
23. Muller,C., Bremer,A., Schreiber,S., Eichwald,S. and Calkhoven,C.F.
(2010) Nucleolar retention of a translational C/EBPalpha isoform
stimulates rDNA transcription and cell size. EMBO J., 29, 897–909.
24. Radomska,H.S., Huettner,C.S., Zhang,P., Cheng,T., Scadden,D.T.
and Tenen,D.G. (1998) CCAAT/enhancer binding protein alpha is a
regulatory switch sufficient for induction of granulocytic
development from bipotential myeloid progenitors.Mol. Cell. Biol.,
18, 4301–4314.
25. Johansen,L.M., Iwama,A., Lodie,T.A., Sasaki,K., Felsher,D.W.,
Golub,T.R. and Tenen,D.G. (2001) c-Myc is a critical target for
c/EBPalpha in granulopoiesis.Mol. Cell. Biol., 21, 3789–3806.
26. Kirstetter,P., Schuster,M.B., Bereshchenko,O., Moore,S., Dvinge,H.,
Kurz,E., Theilgaard-Monch,K., Mansson,R., Pedersen,T.A.,
Pabst,T. et al. (2008) Modeling of C/EBPalpha mutant acute myeloid
leukemia reveals a common expression signature of committed
myeloid leukemia-initiating cells. Cancer Cell, 13, 299–310.
27. Pabst,T., Mueller,B.U., Zhang,P., Radomska,H.S., Narravula,S.,
Schnittger,S., Behre,G., Hiddemann,W. and Tenen,D.G. (2001)
Dominant-negative mutations of CEBPA, encoding
CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute
myeloid leukemia. Nat. Genet., 27, 263–270.
28. Zidek,L.M., Ackermann,T., Hartleben,G., Eichwald,S., Kortman,G.,
Kiehntopf,M., Leutz,A., Sonenberg,N., Wang,Z.Q., von Maltzahn,J.
et al. (2015) Deficiency in mTORC1-controlled C/EBPbeta-mRNA
translation improves metabolic health in mice. EMBO Rep., 16,
1022–1036.
29. Kozak,M. (1987) At least six nucleotides preceding the AUG
initiator codon enhance translation in mammalian cells. J. Mol.
Biol., 196, 947–950.
30. van Gorp,A.G., van der Vos,K.E., Brenkman,A.B., Bremer,A., van
den Broek,N., Zwartkruis,F., Hershey,J.W., Burgering,B.M.,
Calkhoven,C.F. and Coffer,P.J. (2009) AGC kinases regulate
phosphorylation and activation of eukaryotic translation initiation
factor 4B. Oncogene, 28, 95–106.
31. Wethmar,K., Begay,V., Smink,J.J., Zaragoza,K., Wiesenthal,V.,
Dorken,B., Calkhoven,C.F. and Leutz,A. (2010)
C/EBPbetaDeltauORF mice–a genetic model for uORF-mediated
translational control in mammals. Genes Dev., 24, 15–20.
32. Berberich-Siebelt,F., Berberich,I., Andrulis,M., Santner-Nanan,B.,
Jha,M.K., Klein-Hessling,S., Schimpl,A. and Serfling,E. (2006)
SUMOylation interferes with CCAAT/enhancer-binding protein
beta-mediated c-myc repression, but not IL-4 activation in T cells. J.
Immunol., 176, 4843–4851.
33. Muller,C., Calkhoven,C.F., Sha,X. and Leutz,A. (2004) The CCAAT
enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF
complex for proliferation arrest. J. Biol. Chem., 279, 7353–7358.
34. Wiesenthal,V., Leutz,A. and Calkhoven,C.F. (2006) Analysis of
translation initiation using a translation control reporter system.
Nat. Protoc., 1, 1531–1537.
35. Wiesenthal,V., Leutz,A. and Calkhoven,C.F. (2006) A translation
control reporter system (TCRS) for the analysis of translationally
controlled processes in the vertebrate cell. Nucleic Acids Res., 34, e23.
36. Singh,A.M. and Dalton,S. (2009) The cell cycle and Myc intersect
with mechanisms that regulate pluripotency and reprogramming.
Cell Stem Cell, 5, 141–149.
37. Wilson,A., Murphy,M.J., Oskarsson,T., Kaloulis,K., Bettess,M.D.,
Oser,G.M., Pasche,A.C., Knabenhans,C., Macdonald,H.R. and
Trumpp,A. (2004) c-Myc controls the balance between hematopoietic
stem cell self-renewal and differentiation. Genes Dev., 18, 2747–2763.
38. Blum,K.A., Lozanski,G. and Byrd,J.C. (2004) Adult Burkitt
leukemia and lymphoma. Blood, 104, 3009–3020.
39. D’Alo,F., Johansen,L.M., Nelson,E.A., Radomska,H.S.,
Evans,E.K., Zhang,P., Nerlov,C. and Tenen,D.G. (2003) The amino
terminal and E2F interaction domains are critical for C/EBP
alpha-mediated induction of granulopoietic development of
hematopoietic cells. Blood, 102, 3163–3171.
40. Porse,B.T., Pedersen,T.A., Xu,X., Lindberg,B., Wewer,U.M.,
Friis-Hansen,L. and Nerlov,C. (2001) E2F repression by
C/EBPalpha is required for adipogenesis and granulopoiesis in vivo.
Cell, 107, 247–258.
41. Koschmieder,S., D’Alo,F., Radomska,H., Schoneich,C., Chang,J.S.,
Konopleva,M., Kobayashi,S., Levantini,E., Suh,N., Di Ruscio,A.
et al. (2007) CDDO induces granulocytic differentiation of myeloid
leukemic blasts through translational up-regulation of p42 CCAAT
enhancer binding protein alpha. Blood, 110, 3695–3705.
42. Orelio,C., Verkuijlen,P., Geissler,J., van den Berg,T.K. and
Kuijpers,T.W. (2009) SBDS expression and localization at the mitotic
spindle in human myeloid progenitors. PLoS One, 4, e7084.
43. Sen,S., Wang,H., Nghiem,C.L., Zhou,K., Yau,J., Tailor,C.S.,
Irwin,M.S. and Dror,Y. (2011) The ribosome-related protein, SBDS,
is critical for normal erythropoiesis. Blood, 118, 6407–6417.
44. Yamaguchi,M., Fujimura,K., Toga,H., Khwaja,A., Okamura,N. and
Chopra,R. (2007) Shwachman-Diamond syndrome is not necessary
for the terminal maturation of neutrophils but is important for
maintaining viability of granulocyte precursors. Exp. Hematol., 35,
579–586.
45. Schleich,S., Strassburger,K., Janiesch,P.C., Koledachkina,T.,
Miller,K.K., Haneke,K., Cheng,Y.S., Kuchler,K., Stoecklin,G.,
Duncan,K.E. et al. (2014) DENR-MCT-1 promotes translation
re-initiation downstream of uORFs to control tissue growth. Nature,
512, 208–212.
46. Schepetilnikov,M., Dimitrova,M., Mancera-Martinez,E.,
Geldreich,A., Keller,M. and Ryabova,L.A. (2013) TOR and S6K1
promote translation reinitiation of uORF-containing mRNAs via
phosphorylation of eIF3h. EMBO J., 32, 1087–1102.
47. Pisarev,A.V., Skabkin,M.A., Pisareva,V.P., Skabkina,O.V.,
Rakotondrafara,A.M., Hentze,M.W., Hellen,C.U. and Pestova,T.V.
(2010) The role of ABCE1 in eukaryotic posttermination ribosomal
recycling.Mol. Cell, 37, 196–210.
48. Brina,D., Miluzio,A., Ricciardi,S. and Biffo,S. (2015) eIF6
anti-association activity is required for ribosome biogenesis,
translational control and tumor progression. Biochim. Biophys. Acta,
1849, 830–835.
49. Tourlakis,M.E., Zhang,S., Ball,H.L., Gandhi,R., Liu,H., Zhong,J.,
Yuan,J.S., Guidos,C.J., Durie,P.R. and Rommens,J.M. (2015) In Vivo
senescence in the Sbds-deficient murine pancreas: cell-type specific
consequences of translation insufficiency. PLoS Genet., 11,
e1005288.
50. Nerlov,C. (2007) The C/EBP family of transcription factors: a
paradigm for interaction between gene expression and proliferation
control. Trends Cell Biol., 17, 318–324.
51. Rawls,A.S., Gregory,A.D., Woloszynek,J.R., Liu,F. and Link,D.C.
(2007) Lentiviral-mediated RNAi inhibition of Sbds in murine
hematopoietic progenitors impairs their hematopoietic potential.
Blood, 110, 2414–2422.
52. Zambetti,N.A., Bindels,E.M., Van Strien,P.M., Valkhof,M.G.,
Adisty,M.N., Hoogenboezem,R.M., Sanders,M.A., Rommens,J.M.,
Touw,I.P. and Raaijmakers,M.H. (2015) Deficiency of the ribosome
biogenesis gene Sbds in hematopoietic stem and progenitor cells
causes neutropenia in mice by attenuating lineage progression in
myelocytes. Haematologica, 100, 1285–1293.
53. Koschmieder,S., Halmos,B., Levantini,E. and Tenen,D.G. (2009)
Dysregulation of the C/EBPalpha differentiation pathway in human
cancer. .J Clin. Oncol., 27, 619–628.
54. Wang,W., Wang,X., Ward,A.C., Touw,I.P. and Friedman,A.D.
(2001) C/EBPalpha and G-CSF receptor signals cooperate to induce
the myeloperoxidase and neutrophil elastase genes. Leukemia, 15,
779–786.
55. Pabst,T. and Mueller,B.U. (2007) Transcriptional dysregulation
during myeloid transformation in AML. Oncogene, 26, 6829–6837.
 at U
niversity of Cam
bridge on January 18, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
